Intracerebral Hemorrhage
Conditions
Brief summary
The objective of this study is to determine whether minimally invasive soft channel brain hemorrhage evacuation (scMIS), compared to usual care, leads to superior functional recovery as measured by utility-weighted modified Rankin Scale (UW-mRS) scores at 6 months in patients with basal ganglia intracerebral hemorrhage (ICH) of 20 ≤ volume ≤ 30 ml.
Interventions
OTHERUsual Care
During the study treatment and follow-up periods, patients are to receive usual standard of care according to published guidelines for acute stroke care. It is anticipated that background care may include the use of other treatments including drugs and interventions.
PROCEDUREMinimally Invasive Soft Channel Brain Haemorrhage Evacuation (scMIS)
This technique is based on the study of hematoma anatomy, cerebral vascular anatomy, and neural fiber structure anatomy in basal ganglia hemorrhage to determine the optimal surgical (catheter insertion) path. By applying stereogeometric principles, it allows for simple yet precise localization. Through surgical steps including puncture, aspiration, liquefaction (intermittent infusion of urokinase or alteplase), and external drainage, the hematoma can be completely removed in stages over a short period. This ensures that hematoma clearance and decompression of the brain occur simultaneously, achieving a minimally invasive intracerebral hemorrhage evacuation technique with a gradual reduction in intracranial pressure.
Sponsors
Fudan University
Linyi People's Hospital
Capital Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria: 1. Adults (18 - 80 years) ; 2. The clinical diagnosis is acute intracerebral hemorrhage, confirmed by imaging; 3. Onset within 48 hours, and surgery can be initiated within 48 hours; 4. Basal ganglia hemorrhage, with a bleeding volume of 20 ≤ volume ≤ 30 ml; 5. Reduced level of consciousness (GCS 9-14); 6. Pre-stroke mRS score≤1 points; 7. Systolic blood pressure \<140 mmHg before randomisation; 8. Informed consent obtain accordingly to local regulations. *
Exclusion criteria
1. Definite evidence the ICH is secondary to a structural abnormality in the brain (eg arteriovenous malformation, intracranial aneurysm, tumour, trauma, cerebral venous thrombosis) or previous thrombolysis or neurointerventional surgery. 2. A high likelihood that the patient will not adhere to the study treatment and follow-up regimen. 3. Platelet count \< 100,000, INR \> 1.4.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional recovery according to UW-mRS assessed at 6 months | 6 months | Utility weighted modified rankin scale scores is to map functional status (modified Rankin Scale \[mRS\] scores) and health-related quality of life on the European Quality of Life 5-dimensional questionnaire (EQ-5D) to derive utility-weighted (UW) stroke outcome measures. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Discharge at Day 7 (yes vs. no) | 7 days after randomization | Discharge status will be assessed at Day 7 |
| Total length of intensive care unit stay. | During hospitalisation up to 6 months after randomization | The complete length of time a patient is admitted to the intensive care unit (ICU) |
| Ordinal analysis of modified Rankin Scale [mRS] scores at 28 days | 28 days after randomization | Ordinal analysis of modified Rankin Scale \[mRS\] score: 0 =No symptoms at all.1 =No significant disability despite symptoms, able to carry out all usual duties and activities.2 =Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance.3 =Moderate disability requiring some help, but able to walk without Assistance. 4 =Moderate severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance.5 =Severe disability, bedridden incontinent, and requiring constant nursing care and attention.6 =Dead. |
| The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 3-6 | 6-months after randomization | Proportion of subjects with modified Rankin Scale \[mRS\] 3-6 at 6 months after randomization |
| The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 0-6 | 6-months after randomization | Modified Rankin Scale \[mRS\] score at 6 months analysed as an ordinal outcome (categories 0 to 6). |
| The following at 6-months: AMC Linear Disability Score(ALDs) | 6-months after randomization | The AMC (Academic Medical Center) Linear Disability Score (ALDs) is a calibrated generic item bank designed to measure physical disability levels in patients. The ALDs is a sensitive and generic scale that encompasses a broader range of activities compared to the Rankin assessment. The key distinction between the ALDs and the Rankin assessment is that the ALDs provides a linear disability score based on patient-reported outcomes, while the Rankin score is an ordinal assessment determined by a rater. |
| The following at 6-months: EuroQoL Group 5-Dimension self-report questionnaire (EQ-5D) | 6-months after randomization | An EQ-5D score, also referred to as an EQ-5D value index or utility, quantifies a person's health status on a scale from 1 (full health) to 0 (equivalent to being dead). Negative values may be assigned to health states considered worse than death.The score is calculated using a formula that applies specific weights to each level in the various dimensions of the EQ-5D, with these weights derived from a value set that includes index values for all possible EQ-5D states. |
| Days of hospitalization | During hospitalisation up to 6 months after randomization | Length of stay in hospital |
| The following at 6-months: ordinal analysis of modified Rankin Scale [mRS] scores 3-5 | 6-months after randomization | Proportion of subjects with modified Rankin Scale \[mRS\] 3-5 at 6 months after randomization |
Other
| Measure | Time frame | Description |
|---|---|---|
| Safety outcomes | Throughout the entire study period up to 6 months after randomization | Mortality, rebleeding, infections, and other serious adverse events (SAEs) recorded throughout the entire study period. |
Countries
China
Outcome results
None listed